Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications Agilent Technologies Inc. (NYSE: A) today ...

When used in conjunction with the PD-L1 IHC 28-8 pharmDx as a companion test, in the European Union: (a) resectable NSCLC patients with PD-L1 expression ≥1% and at high risk of recurrence may be ...

ISLAMABAD: Islamabad High Court (IHC) has issued notices to secretary Ministry of Law and Justice, chairman Federal Public ...

Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...

Breast cancer is the most prevalent in Nigeria with over 32,000 cases yearly. Half of the women diagnosed with breast cancer ...

The precision cancer business of PHC Holdings anticipates an increase in cancer cases and is expanding its digital pathology and immunohistochemistry instrument lineup.

Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma—the most common ...

A multinational healthcare company, Roche and a provider of digital integrated healthcare services, Oncopadi Technologies ...

The programme aims to enhance early detection and ensure timely, accurate breast cancer diagnosis by offering free immunohistochemistry tests, multidisciplinary care, and navigation services to 5,000 ...